Involvement of non-Helicobacter pylori helicobacter infections in Helicobacter pylori-negative gastric MALT lymphoma pathogenesis and efficacy of eradication therapy
- 27 February 2021
- journal article
- research article
- Published by Springer Nature in Gastric Cancer
- Vol. 24 (4) , 937-945
Abstract
Background Eradication therapy is known to be effective against Helicobacter pylori-positive gastric MALT lymphoma but predicting the efficacy of eradication therapy against Helicobacter pylori-negative gastric MALT lymphoma is difficult. Recent reports have shown that non-Helicobacter pylori helicobacter infections induce gastric MALT lymphoma, and we aimed to clarify whether non-Helicobacter pylori helicobacter infections are associated with the efficacy of eradication therapy. Methods We analyzed eradication therapy as a first-line treatment for 182 cases of gastric MALT lymphoma, classified according to Helicobacter pylori infection and API2-MALT1 mutation status. We also evaluated the non-Helicobacter pylori helicobacter infection status in 29 Helicobacter pylori-negative cases via PCR with DNA extracted from paraffin-embedded biopsy tissues. Finally, we analyzed the relationship between non-Helicobacter pylori helicobacter infection status and eradication therapy outcome. Results The API2-MALT1 mutation was observed in 13/182 patients (7.1%), none of whom were cured by eradication therapy. Helicobacter pylori-negative cases had a significantly higher non-Helicobacter pylori helicobacter infection rate than Helicobacter pylori-positive cases (16/29, 55% vs. 3/29, 10%; P < 0.05). Among the Helicobacter pylori-negative cases, non-Helicobacter pylori helicobacter-positive cases had a significantly higher complete response rate than non-Helicobacter pylori helicobacter-negative cases (12/16, 75% vs. 3/13, 23%; P < 0.05). Conclusion Helicobacter pylori-negative and API2-MALT1-negative gastric MALT lymphoma cases exhibited a high rate of non-Helicobacter pylori helicobacter infections, which may have contributed to the success of eradication therapy. Therefore, we recommend eradication therapy as a first-line treatment for non-Helicobacter pylori helicobacter-positive gastric MALT lymphoma.Keywords
Funding Information
- PUH Research Grant Program
This publication has 43 references indexed in Scilit:
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Primary gastrointestinal lymphomaWorld Journal of Gastroenterology, 2011
- Gastric Helicobacters in Domestic Animals and Nonhuman Primates and Their Significance for Human HealthClinical Microbiology Reviews, 2009
- “ Candidatus Helicobacter heilmannii” from a Cynomolgus Monkey Induces Gastric Mucosa-Associated Lymphoid Tissue Lymphomas in C57BL/6 MiceInfection and Immunity, 2007
- Helicobacter heilmannii-associated Gastritis: Clinicopathologic Findings and Comparison withHelicobacter pylori-associated GastritisJournal of Korean Medical Science, 2007
- Helicobacter heilmannii infection: Clinical, endoscopic and histopathological features in Japanese patientsPathology International, 2005
- Description of ‘Candidatus Helicobacter heilmannii’ based on DNA sequence analysis of 16S rRNA and urease genesInternational Journal of Systematic and Evolutionary Microbiology, 2004
- MALIGNANT TUMORS OF THE STOMACHGastroenterology Clinics of North America, 2000
- Helicobacter heilmannii Associated Erosive Gastritis.Internal Medicine, 1999
- Gastrointestinal involvement in non-Hodgkin's lymphomaCancer, 1980